These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6310403)

  • 1. Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides.
    Emini EA; Jameson BA; Wimmer E
    Nature; 1983 Aug 25-31; 304(5928):699-703. PubMed ID: 6310403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide priming of a poliovirus neutralizing antibody response.
    Wimmer E; Emini EA; Jameson BA
    Rev Infect Dis; 1984; 6 Suppl 2():S505-9. PubMed ID: 6330847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the complex between the Fab fragment of a neutralizing antibody for type 1 poliovirus and its viral epitope.
    Wien MW; Filman DJ; Stura EA; Guillot S; Delpeyroux F; Crainic R; Hogle JM
    Nat Struct Biol; 1995 Mar; 2(3):232-43. PubMed ID: 7539711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a monoclonal antibody and of DNA recombinant technology for the localization of a poliovirus neutralization epitope in viral capsid polypeptide VP1.
    Bruneau P; van der Werf S; Wychowski C; Siffert O; Girard M
    Dev Biol Stand; 1984; 57():177-85. PubMed ID: 6084609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies.
    Chow M; Yabrov R; Bittle J; Hogle J; Baltimore D
    Proc Natl Acad Sci U S A; 1985 Feb; 82(3):910-4. PubMed ID: 2983321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
    Evans DM; Minor PD; Schild GS; Almond JW
    Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
    Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
    J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for several unrelated neutralization epitopes of poliovirus, type 1, strain Mahoney, provided by neutralization tests and quantitative enzyme-linked immunosorbent assay (ELISA).
    Uhlig H; Rutter G; Dernick R
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2809-12. PubMed ID: 6198443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species.
    Emini EA; Schleif WA; Jameson BA; Wimmer E
    J Virol Methods; 1985 Feb; 10(2):163-70. PubMed ID: 2984231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus.
    Meloen RH; Puyk WC; Meijer DJ; Lankhof H; Posthumus WP; Schaaper WM
    J Gen Virol; 1987 Feb; 68 ( Pt 2)():305-14. PubMed ID: 2434606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of retro-inverso peptides as synthetic vaccines.
    Van Regenmortel MH; Guichard G; Benkirane N; Briand JP; Muller S; Brown F
    Dev Biol Stand; 1998; 92():139-43. PubMed ID: 9554267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.
    Chow M; Baltimore D
    Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7518-21. PubMed ID: 6296837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.
    Ferguson M; Evans DM; Magrath DI; Minor PD; Almond JW; Schild GC
    Virology; 1985 Jun; 143(2):505-15. PubMed ID: 2414909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new neutralization antigenic site on poliovirus coat protein VP2.
    Emini EA; Jameson BA; Wimmer E
    J Virol; 1984 Nov; 52(2):719-21. PubMed ID: 6208380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of monoclonal antibodies raised against a synthetic peptide capable of inducing a neutralizing response to human rhinovirus type 2.
    Barnett PV; Rowlands DJ; Parry NR
    J Gen Virol; 1993 Jul; 74 ( Pt 7)():1295-302. PubMed ID: 8393073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and potential use of monoclonal antibodies against polio viruses.
    Osterhaus AD; van Wezel AL; van Steenis G; Hazendonk AG; Drost G
    Dev Biol Stand; 1981; 50():221-8. PubMed ID: 6281107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivity of neutralizing antibodies with different specificities to H particles of poliovirus.
    Urasawa T; Urasawa S; Taniguchi K
    Microbiol Immunol; 1979; 23(7):651-7. PubMed ID: 228166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.